VEGFA and acute myeloid leukemia: It was furthermore shown that SEMA3A may partially reverse VEGF-induced proliferation of acute myeloid leukemia (AML) cells, and the combined administration of VEGF inhibitors and recombinant SEMA3A was suggested as potential treatment for AML patients (21).